lapatinib has been researched along with Carcinoma, Papillary in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, L; Cheng, L; Jin, Y; Liu, M; Ruan, M | 1 |
Cancello, G; Colleoni, M; Montagna, E; Rizzo, S; Scarano, E; Torrisi, R | 1 |
2 other study(ies) available for lapatinib and Carcinoma, Papillary
Article | Year |
---|---|
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Topics: Benzimidazoles; Blotting, Western; Carcinoma, Papillary; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Imidazoles; Inhibitory Concentration 50; Lapatinib; MAP Kinase Kinase 1; Microscopy, Fluorescence; Mutation, Missense; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms | 2017 |
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Papillary; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |